A Single-Centre, Double Blind, Randomized, Two-Way Cross-Over Study of Repeated Doses of AZD3480 and Single Dose of Warfarin to Evaluate the Pharmacokinetic Interaction of AZD3480 and Warfarin and the Effect of AZD3480 Pharmacodynamic in Healthy Male Subjects (Phase I)

Trial Profile

A Single-Centre, Double Blind, Randomized, Two-Way Cross-Over Study of Repeated Doses of AZD3480 and Single Dose of Warfarin to Evaluate the Pharmacokinetic Interaction of AZD3480 and Warfarin and the Effect of AZD3480 Pharmacodynamic in Healthy Male Subjects (Phase I)

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2013

At a glance

  • Drugs Ispronicline (Primary) ; Warfarin
  • Indications Alzheimer's disease; Thromboembolism
  • Focus Pharmacokinetics
  • Acronyms DDI
  • Most Recent Events

    • 18 Apr 2009 Planned end date changed from 1 Jan 2009 to 1 May 2009 as reported by ClinicalTrials.gov
    • 18 Apr 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Status changed from recruiting to suspended due to the observation of a serious adverse event in another ispronicline trial according to ClinicalTrials.gov; the trial has been temporarily suspended during further evaluation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top